Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children?

Gold MS, Blum K, Oscar-Berman M, Braverman ER.

Postgrad Med. 2014 Jan;126(1):153-77. doi: 10.3810/pgm.2014.01.2735. Review.

2.

Examining for association between candidate gene polymorphisms in the dopamine pathway and attention-deficit hyperactivity disorder: a family-based study.

Payton A, Holmes J, Barrett JH, Hever T, Fitzpatrick H, Trumper AL, Harrington R, McGuffin P, O'Donovan M, Owen M, Ollier W, Worthington J, Thapar A.

Am J Med Genet. 2001 Jul 8;105(5):464-70.

PMID:
11449400
3.

Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Froehlich TE, McGough JJ, Stein MA.

CNS Drugs. 2010 Feb;24(2):99-117. doi: 10.2165/11530290-000000000-00000. Review.

4.

Association between the polymorphisms of the selected genes encoding dopaminergic system with ADHD and autism.

Nikolac Perkovic M, Nedic Erjavec G, Stefulj J, Muck-Seler D, Pivac N, Kocijan Hercigonja D, Hranilovic D, Curkovic M, Dodig-Curkovic K.

Psychiatry Res. 2014 Jan 30;215(1):260-1. doi: 10.1016/j.psychres.2013.10.018. Epub 2013 Oct 24. No abstract available.

PMID:
24210742
5.

Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children.

Kereszturi E, Tarnok Z, Bognar E, Lakatos K, Farkas L, Gadoros J, Sasvari-Szekely M, Nemoda Z.

Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1431-5. doi: 10.1002/ajmg.b.30704.

PMID:
18214865
6.

Evaluation of potential gene-gene interactions for attention deficit hyperactivity disorder in the Han Chinese population.

Qian Q, Wang Y, Li J, Yang L, Wang B, Zhou R, Glatt SJ, Faraone SV.

Am J Med Genet B Neuropsychiatr Genet. 2007 Mar 5;144B(2):200-6.

PMID:
17044099
7.

Association of dopaminergic/GABAergic genes with attention deficit hyperactivity disorder in children.

Wang GX, Ma YH, Wang SF, Ren GF, Guo H.

Mol Med Rep. 2012 Nov;6(5):1093-8. doi: 10.3892/mmr.2012.1028. Epub 2012 Aug 9.

PMID:
22895683
8.

Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.

Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB, Graham AJ, Langberg JM, Kahn RS.

J Am Acad Child Adolesc Psychiatry. 2011 Nov;50(11):1129-1139.e2. doi: 10.1016/j.jaac.2011.08.002. Epub 2011 Sep 15.

9.

Spatial attentional bias as a marker of genetic risk, symptom severity, and stimulant response in ADHD.

Bellgrove MA, Barry E, Johnson KA, Cox M, Dáibhis A, Daly M, Hawi Z, Lambert D, Fitzgerald M, McNicholas F, Robertson IH, Gill M, Kirley A.

Neuropsychopharmacology. 2008 Sep;33(10):2536-45. Epub 2007 Nov 28.

10.

Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit/hyperactivity disorder: is there an interaction?

Hong SB, Kim JW, Cho SC, Shin MS, Kim BN, Yoo HJ.

J Child Adolesc Psychopharmacol. 2012 Oct;22(5):343-52. doi: 10.1089/cap.2011.0076.

PMID:
23083021
11.

Association of the dopamine beta hydroxylase gene with attention deficit hyperactivity disorder: genetic analysis of the Milwaukee longitudinal study.

Smith KM, Daly M, Fischer M, Yiannoutsos CT, Bauer L, Barkley R, Navia BA.

Am J Med Genet B Neuropsychiatr Genet. 2003 May 15;119B(1):77-85.

PMID:
12707943
12.

Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.

Molina BS, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, Hoza B, Epstein JN, Wigal T, Abikoff HB, Greenhill LL, Jensen PS, Wells KC, Vitiello B, Gibbons RD, Howard A, Houck PR, Hur K, Lu B, Marcus S; MTA Cooperative Group.

J Am Acad Child Adolesc Psychiatry. 2013 Mar;52(3):250-63. doi: 10.1016/j.jaac.2012.12.014. Epub 2013 Feb 8.

13.

A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder.

McGough JJ, McCracken JT, Loo SK, Manganiello M, Leung MC, Tietjens JR, Trinh T, Baweja S, Suddath R, Smalley SL, Hellemann G, Sugar CA.

J Am Acad Child Adolesc Psychiatry. 2009 Dec;48(12):1155-64. doi: 10.1097/CHI.0b013e3181bc72e3.

14.
15.

A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.

Kollins SH.

Curr Med Res Opin. 2008 May;24(5):1345-57. doi: 10.1185/030079908X280707 . Epub 2008 Apr 1. Review.

PMID:
18384709
16.

Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents.

Wilens TE, Adamson J, Monuteaux MC, Faraone SV, Schillinger M, Westerberg D, Biederman J.

Arch Pediatr Adolesc Med. 2008 Oct;162(10):916-21. doi: 10.1001/archpedi.162.10.916.

17.

Differential associations of dopamine-related polymorphisms with discrete components of reaction time variability: relevance for attention deficit/hyperactivity disorder.

Grant P, Kuepper Y, Wielpuetz C, Hennig J.

Neuropsychobiology. 2014;69(4):220-6. doi: 10.1159/000360367. Epub 2014 Jun 18.

PMID:
24942140
18.

Update on attention-deficit/hyperactivity disorder.

Daley KC.

Curr Opin Pediatr. 2004 Apr;16(2):217-26. Review.

PMID:
15021207
19.

Schizotypy, attention deficit hyperactivity disorder, and dopamine genes.

Ettinger U, Joober R, DE Guzman R, O'driscoll GA.

Psychiatry Clin Neurosci. 2006 Dec;60(6):764-7.

20.

Prenatal smoking exposure and dopaminergic genotypes interact to cause a severe ADHD subtype.

Neuman RJ, Lobos E, Reich W, Henderson CA, Sun LW, Todd RD.

Biol Psychiatry. 2007 Jun 15;61(12):1320-8. Epub 2006 Dec 6.

PMID:
17157268

Supplemental Content

Support Center